Compare Stocks

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$55.05 -2.0%	$73.26	$37.55 ▼ $91.10	$4.67B	1.76	1.85 million shs	1.77 million shs
NIO NIO	$3.80 -5.2%	$5.17	$3.71 ▼ $16.18	$6.52B	1.93	56.20 million shs	35.69 million shs
TWLO Twilio	$57.55 -1.5%	$61.02	$45.02 ▼ $78.16	$10.42B	1.35	3.32 million shs	2.03 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	+1.08%	-10.73%	-21.96%	-9.40%	+5.01%
NIO NIO	+1.92%	-10.64%	-23.27%	-34.16%	-54.61%
TWLO Twilio	-0.54%	-4.76%	-5.16%	-20.38%	-0.93%

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	2.4376 of 5 stars	4.2	1.0	0.0	2.0	2.5	0.6
NIO NIO	1.8529 of 5 stars	4.0	2.0	0.0	1.7	0.8	0.6
TWLO Twilio	4.0908 of 5 stars	3.2	5.0	3.1	2.0	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.38	Hold	$76.29	38.58% Upside
NIO NIO	1.91	Reduce	$8.43	122.00% Upside
TWLO Twilio	2.32	Hold	$68.90	19.72% Upside

Current Analyst Ratings

Latest NIO, TWLO, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$88.00 ➝ $89.00
4/17/2024	TWLO Twilio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$75.00
4/15/2024	NIO NIO	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$5.00
4/11/2024	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$90.00
4/2/2024	NIO NIO	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Underweight	$5.00 ➝ $4.00
3/25/2024	NIO NIO	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$5.50
3/14/2024	NIO NIO	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.20
3/7/2024	NIO NIO	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform ➝ Market Perform	$7.50 ➝ $5.50
3/6/2024	CRSP CRISPR Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$82.00 ➝ $99.00
3/6/2024	NIO NIO	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$7.50 ➝ $6.50
3/6/2024	NIO NIO	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$8.30 ➝ $5.90

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$371.21M	12.59	N/A	N/A	$23.70 per share	2.32
NIO NIO	$7.83B	0.83	N/A	N/A	$2.11 per share	1.80
TWLO Twilio	$4.15B	2.51	$0.80 per share	71.50	$53.76 per share	1.07

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$153.61M	-$1.96	N/A	N/A	N/A	N/A	-8.09%	-6.73%	5/13/2024 (Estimated)
NIO NIO	-$2.94B	-$1.75	N/A	N/A	N/A	-38.09%	-110.72%	-21.32%	6/14/2024 (Estimated)
TWLO Twilio	-$1.02B	-$5.54	N/A	169.26	N/A	-24.44%	-1.66%	-1.39%	5/7/2024 (Confirmed)

Latest NIO, TWLO, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2024	N/A	TWLO Twilio	$0.60	N/A	-$0.60	N/A	N/A	N/A
3/5/2024	12/31/2023	NIO NIO	-$2.39	-$2.81	-$0.42	-$0.45	$18.16 billion	$17.10 billion
2/21/2024	Q4 2023	CRSP CRISPR Therapeutics	$0.15	$1.10	+$0.95	$1.10	$148.72 million	$201.20 million
2/14/2024	Q4 2023	TWLO Twilio	-$0.20	-$0.03	+$0.17	$1.95	$1.04 billion	$1.08 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NIO NIO	N/A	N/A	N/A	N/A	N/A
TWLO Twilio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	17.54	17.54
NIO NIO	0.51	1.22	1.13
TWLO Twilio	0.10	6.64	6.64

Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
NIO NIO	48.55%
TWLO Twilio	84.27%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.10%
NIO NIO	1.00%
TWLO Twilio	4.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	473	84.88 million	81.40 million	Optionable
NIO NIO	32,820	1.72 billion	1.70 billion	Optionable
TWLO Twilio	5,867	181.04 million	173.44 million	Optionable

NIO, TWLO, and CRSP Headlines

Source	Headline
	Why Twilio (TWLO) Dipped More Than Broader Market Today zacks.com - April 19 at 6:51 PM
	Who Owns Telegram? fool.com - April 19 at 12:14 AM
	Twilio Inc. (NYSE:TWLO) Shares Sold by Vontobel Holding Ltd. marketbeat.com - April 18 at 6:14 AM
	Twilio (NYSE:TWLO) Receives "Outperform" Rating from Oppenheimer americanbankingnews.com - April 18 at 5:52 AM
	New Twilio study shows Australian brands greatly overestimate consumer perception itwire.com - April 18 at 12:42 AM
	Here's Why Twilio (TWLO) Fell More Than Broader Market zacks.com - April 17 at 7:06 PM
	Twilio (NYSE:TWLO) Receives Outperform Rating from Oppenheimer marketbeat.com - April 17 at 3:37 PM
	A Closer Look at 16 Analyst Recommendations For Twilio markets.businessinsider.com - April 17 at 2:42 PM
	Twilio: Valuation Now Attractive (Rating Upgrade) seekingalpha.com - April 17 at 12:35 AM
	Twilio Stock (NASDAQ:TWLO) Has Underdelivered, But It Can Turn Around markets.businessinsider.com - April 17 at 12:35 AM
	Peering Into Twilio's Recent Short Interest benzinga.com - April 16 at 2:34 PM
	Twilio GC Sees Pay Drop 73% in 2023 law.com - April 15 at 5:39 PM
	The Zacks Analyst Blog Highlights Microsoft, NVIDIA, Twilio, Meta Platforms and Zscaler finance.yahoo.com - April 15 at 12:38 PM
	Investors Heavily Search Twilio Inc. (TWLO): Here is What You Need to Know zacks.com - April 15 at 10:01 AM
	Wells Fargo Sticks to Their Hold Rating for Twilio (TWLO) markets.businessinsider.com - April 15 at 2:37 AM
	Sumitomo Mitsui Trust Holdings Inc. Trims Stock Holdings in Twilio Inc. (NYSE:TWLO) marketbeat.com - April 14 at 1:20 PM
	Lecap Asset Management Ltd. Invests $2.30 Million in Twilio Inc. (NYSE:TWLO) marketbeat.com - April 13 at 7:52 PM
	4 AI Stocks With Ample Growth Potential to Buy in 2024 zacks.com - April 12 at 10:41 AM
	AI Takes Center Stage In Twilio’s 2024 State Of Customer Engagement Report forbes.com - April 12 at 9:25 AM
	International Assets Investment Management LLC Purchases 247,042 Shares of Twilio Inc. (NYSE:TWLO) marketbeat.com - April 12 at 4:55 AM
	Twilio (TWLO) Stock Drops Despite Market Gains: Important Facts to Note zacks.com - April 11 at 6:56 PM
	DekaBank Deutsche Girozentrale Sells 32,553 Shares of Twilio Inc. (NYSE:TWLO) marketbeat.com - April 11 at 5:51 AM
	Baillie Gifford & Co. Cuts Stock Holdings in Twilio Inc. (NYSE:TWLO) marketbeat.com - April 10 at 8:24 AM
	Twilio: 20% Share Buyback Incoming seekingalpha.com - April 10 at 12:35 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Nio Stock Price Is On Track for Penny-Stock Status
March 21, 2024 6:05 AM
View Nio Stock Price Is On Track for Penny-Stock Status

All Headlines

Company Descriptions

CRISPR Therapeutics

NASDAQ:CRSP

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

NIO

NYSE:NIO

NIO Inc. designs, manufactures, and sells electric vehicles in the People's Republic of China. The company is also involved in the manufacture of e-powertrain, battery packs, and components; and racing management, technology development, and sales and after-sales management activities. In addition, it offers power solutions for battery charging needs; and other value-added services. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Twilio

NYSE:TWLO

Twilio Inc., together with its subsidiaries, provides customer engagement platform solutions in the United States and internationally. It operates through two segments, Twilio Communications and Twilio Segment. The company provides various application programming interfaces and software solutions for communications between customers and end users, including messaging, voice, email, flex, marketing campaigns, and user identity and authentication. It also offers software products to build direct, personalized relationships with their end users, such as segment, a platform that provides tools for first-party data by unifying real-time information collected; and engage, an automation platform for the delivery of omnichannel campaigns. Twilio Inc. was incorporated in 2008 and is headquartered in San Francisco, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial